Home Other Building Blocks Talarozole

Talarozole

CAS No.:
201410-53-9
Catalog Number:
AG002DDL
Molecular Formula:
C21H23N5S
Molecular Weight:
377.5058
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
2mg
99%
1 week
United States
$223
- +
5mg
99%
1 week
United States
$290
- +
10mg
99%
1 week
United States
$357
- +
50mg
99%
1 week
United States
$723
- +
100mg
99%
1 week
United States
$1140
- +
Product Description
Catalog Number:
AG002DDL
Chemical Name:
Talarozole
CAS Number:
201410-53-9
Molecular Formula:
C21H23N5S
Molecular Weight:
377.5058
MDL Number:
MFCD17166995
IUPAC Name:
N-[4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl]-1,3-benzothiazol-2-amine
InChI:
InChI=1S/C21H23N5S/c1-3-15(4-2)20(26-14-22-13-23-26)16-9-11-17(12-10-16)24-21-25-18-7-5-6-8-19(18)27-21/h5-15,20H,3-4H2,1-2H3,(H,24,25)
InChI Key:
SNFYYXUGUBUECJ-UHFFFAOYSA-N
SMILES:
CCC(C(n1cncn1)c1ccc(cc1)Nc1nc2c(s1)cccc2)CC
Properties
Complexity:
452  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
377.167g/mol
Formal Charge:
0
Heavy Atom Count:
27  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
377.51g/mol
Monoisotopic Mass:
377.167g/mol
Rotatable Bond Count:
7  
Topological Polar Surface Area:
83.9A^2
Undefined Atom Stereocenter Count:
1  
Undefined Bond Stereocenter Count:
0
XLogP3:
6  
Literature
Title Journal
Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids. Molecular pharmacology 20150301
Homology models of human all-trans retinoic acid metabolizing enzymes CYP26B1 and CYP26B1 spliced variant. Journal of chemical information and modeling 20121022
Cloning and functional studies of a splice variant of CYP26B1 expressed in vascular cells. PloS one 20120101
Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26). Journal of medicinal chemistry 20111013
Complete meiosis from human induced pluripotent stem cells. Stem cells (Dayton, Ohio) 20110801
Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates. Journal of medicinal chemistry 20110428
CYP26B1 plays a major role in the regulation of all-trans-retinoic acid metabolism and signaling in human aortic smooth muscle cells. Journal of vascular research 20110101
Local skin pharmacokinetics of talarozole, a new retinoic acid metabolism-blocking agent. Skin pharmacology and physiology 20110101
CYP26A1-specific antagonist influence on embryonic implantation, gene expression and endogenous retinoid concentration in rats. Reproductive toxicology (Elmsford, N.Y.) 20101101
Both all-trans retinoic acid and cytochrome P450 (CYP26) inhibitors affect the expression of vitamin A metabolizing enzymes and retinoid biomarkers in organotypic epidermis. Archives of dermatological research 20090801
The CYP26 inhibitor R115866 potentiates the effects of all-trans retinoic acid on cultured human epidermal keratinocytes. The British journal of dermatology 20090301
The involvement of cytochrome p450 (CYP) 26 in the retinoic acid metabolism of human epidermal keratinocytes. Biochimica et biophysica acta 20090301
Topical treatment with CYP26 inhibitor talarozole (R115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis. The British journal of dermatology 20090101
Talarozole, a selective inhibitor of P450-mediated all-trans retinoic acid for the treatment of psoriasis and acne. Current opinion in investigational drugs (London, England : 2000) 20081101
Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology 20080601
Oral R115866 in the treatment of moderate to severe plaque-type psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 20070901
Oral R115866 in the treatment of moderate to severe facial acne vulgaris: an exploratory study. The British journal of dermatology 20070701
CYP26 inhibitor R115866 increases retinoid signaling in intimal smooth muscle cells. Arteriosclerosis, thrombosis, and vascular biology 20070701
Oral retinoic acid metabolism blocking agent Rambazole for plaque psoriasis: an immunohistochemical study. The British journal of dermatology 20070201
Cyp26 enzymes generate the retinoic acid response pattern necessary for hindbrain development. Development (Cambridge, England) 20070101
Cyp26 genes a1, b1 and c1 are down-regulated in Tbx1 null mice and inhibition of Cyp26 enzyme function produces a phenocopy of DiGeorge Syndrome in the chick. Human molecular genetics 20061201
Homology model of human retinoic acid metabolising enzyme cytochrome P450 26A1 (CYP26A1): active site architecture and ligand binding. Journal of enzyme inhibition and medicinal chemistry 20060801
Retinoic acid regulates sex-specific timing of meiotic initiation in mice. Proceedings of the National Academy of Sciences of the United States of America 20060221
Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. European journal of pharmacology 20050601
Patterning of motor neurons by retinoic acid in the chick embryo hindbrain in vitro. Molecular and cellular neurosciences 20030501
R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents. The Journal of pharmacology and experimental therapeutics 20000401
Properties